Impact Biomedical Inc.
IBO NYSE· Pharmaceutical Preparations
Last close · Oct 27, 2026
$3.55
KIRA · Stoqly’s AI analyst, in plain words
- Impact Biomedical Inc. had $0.0M of revenue in fiscal 2025.
- Its operating margin was −13,381.3%: of every 100 in sales, about −13,381 is left after running the business.
- Impact Biomedical Inc. lost $11.8M in fiscal 2025.
Market cap
—
P/E
4.0x
Revenue
$0.0M
Net income
−$11.8M
Free cash flow
—
Operating margin
−13,381.3%
Impact Biomedical Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−36,993.8%
No. It lost money last year.
How is the share priced?
4.0x
One share costs 4.0 times its yearly profit per share.
What Impact Biomedical Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 11, 2026
- Legal name
- IMPACT BIOMEDICAL INC.
- CIK
- 0001834105
Impact Biomedical Inc. · IBO
Results and finances
The last 4 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Sales and profit | ||||
| Revenue | $0.1M | — | — | $0.0M |
| Gross margin | — | — | — | −1,225.0% |
| Operating margin | −6,808.0% | — | — | −13,381.3% |
| Net income | −$7.3M | −$4.3M | −$24.7M | −$11.8M |
| Net margin | −14,510.0% | — | — | −36,993.8% |
| Diluted EPS | −$0.10 | −$0.07 | −$2.30 | −$0.38 |
| Cash | ||||
| Cash from operations | −$2.2M | −$2.9M | −$2.9M | −$1.9M |
| Debt and strength | ||||
| Cash and short-term investments | $0.0M | $0.0M | $2.0M | $0.0M |
| Shareholders' equity | $29.6M | $25.2M | $4.3M | $12.3M |
| Current ratio | 0.0x | 0.0x | 0.3x | 0.4x |
| Interest coverage | −7.4x | −9.1x | −27.0x | −5.4x |
| Returns and quality | ||||
| Return on equity | −24.5% | −15.8% | −167.6% | −142.9% |
| Altman Z'' | −0.3 | −1.8 | −17.6 | −4.2 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.1M
3 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Impact Biomedical Inc. · IBO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.55 a share, the company is worth —: 4.0 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001834105). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.